ArticleJournal of the European Academy of Dermatology and Venereology : JEADV2026
Tocilizumab for severe and refractory mucous membrane pemphigoid.
Article in Journal of the European Academy of Dermatology and Venereology : JEADV, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Tocilizumab for severe and refractory mucous membrane pemphigoid.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
Abstract
backgroundMucous membrane pemphigoid (MMP) is a rare autoimmune blistering disease involving mucous membranes with a potentially devastating fibrosing course. Laryngotracheal and/or oesophageal involvement may lead to life-threatening complications, while corneal involvement may lead to blindness.
objectivesTo characterize the serum cytokine profile of MMP and to evaluate the efficacy of tocilizumab in nine cases of severe MMP according to the serum levels of IL-6.
methodsSera from MMP patients were compared to sex- and age-matched healthy donors (HD) and patients with bullous pemphigoid (BP), using two proteomic assays (Olink and Luminex). The Olink assay included 40 MMP, 40 BP and 40 HD sera, and the Luminex assay included 63 MMP, 31 BP and 24 HD sera. Based on these findings, nine patients with severe and refractory MMP received tocilizumab on a compassionate use basis after failure of standard therapies.
resultsProteomic analyses revealed high serum levels of IL-6, IL-8, MIP-1α/CCL3 and MIP-1β/CCL4 in MMP compared to BP and HD. Patients with MMP who achieved complete remission during follow-up had lower baseline serum levels of IL-6 (p < 0.0001), IL-8 (p = 0.0382), MIP-1α/CCL3 (p = 0.0005) and MIP-1β/CCL4 (p = 0.0009) than those with persistent disease activity. Nine patients with severe and refractory MMP were treated with tocilizumab. Their mean MMPDAI score decreased from 14.8 ± 6.6 to 4.2 ± 3.2 (p = 0.009). At the last evaluation, seven patients (78%) were in partial remission, one (11%) in complete remission and one (11%) recently treated achieved control of disease activity. Baseline IL-6 was elevated in five of eight tested patients; all three with normal IL-6 levels improved clinically. Four non-severe adverse events were observed (two neutropenias, one thrombocytopenia, one hepatic cytolysis).
conclusionsProteomic analyses identified a distinct MMP cytokine profile with increased IL-6, IL-8, MIP-1α/CCL3 and MIP-1β/CCL4, supporting IL-6 targeting, with tocilizumab as a potential option in severe refractory MMP.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.